| Literature DB >> 30245707 |
Supun Katugampala1, Inoka C Perera2, Chandrika Nanayakkara3, Theshini Perera1.
Abstract
Metallotriazine complexes possess interesting biological and medicinal properties, and the present study focuses on the synthesis, characterization, and antimicrobial activity of four novel copper-triazine derivatives in search of potent antibacterial and antifungal drug leads. In this study, 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-4,4'-disulfonic acid monosodium salt (L1, ferrozine) and 3-(2-pyridyl)-5,6-di(2-furyl)-1,2,4-triazine-5,5'-disulfonic acid disodium salt (L2, ferene) have been used as ligands to study the complexation towards copper(II). The synthesized complexes, [CuCl2(ferrozine)]·7H2O·MeOH (1), [CuCl2(ferrozine)2]·5H2O·MeOH (2), [CuCl2(ferene)]·H2O·MeOH (3), and [CuCl2(ferene)2]·H2O·MeOH (4), have been characterized spectroscopically, and preliminary bioassays have been carried out. FTIR spectroscopic data have shown that N=N and C=N stretching frequencies of complexes have been shifted towards lower frequencies in comparison with that of the ligands, confirming new bond formation between Cu and N, which in turn lowers the strength of N=N and C=N bonds. In addition, a bathochromic shift has been observed for UV-visible spectra of complexes (1), (2), (3), and (4). Furthermore, elemental analysis data have been useful to obtain empirical formulas of these complexes and to establish the purity of each complex. Complexes (1) and (2) have shown antibacterial activity for both S. aureus (ATCC® 25923) and E. coli (ATCC® 25922) at 1 mg/disc concentration, and ferrozine has shown a larger inhibition zone against the clinical sample of C. albicans at 1 mg/disc concentration in comparison with the positive control, fluconazole.Entities:
Year: 2018 PMID: 30245707 PMCID: PMC6136538 DOI: 10.1155/2018/2530851
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Figure 1Structure of 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt (L1) (a) and 3-(2-pyridyl)-5,6-di(2-furyl)-1,2,4-triazine-5,5′-disulfonic acid disodium salt (L2) (b).
Figure 2Synthetic routes for ML1Cl2 (complex (1)) (i), M(L1)2Cl2 (complex (2)) (ii), ML2Cl2 (complex (3)) (iii), and M(L2)2Cl2 (complex (4)) (iv) complexes. NB: L1 = 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt; L2 = 3-(2-pyridyl)-5,6-di(2-furyl)-1,2,4-triazine-5,5′-disulfonic acid disodium salt. Solvent molecules in complexes (1)–(4) have been omitted for clarity. Molar ratios of reactants: (i) CuCl2 : L1 = 1 : 1, (ii) CuCl2 : L1 = 1 : 2, (iii) CuCl2 : L2 = 1 : 1, and (iv) CuCl2 : L2 = 1 : 2.
FTIR data comparison chart of complexes (1)–(4) in comparison with those of free ligands.
|
|
| |
|---|---|---|
| Ferrozine | 1608 | 1503 |
| Complex ( | 1596 | 1498 |
| Complex ( | 1595 | 1498 |
| Ferene | 1589 | 1507 |
| Complex ( | 1567 | 1499 |
| Complex ( | 1570 | 1494 |
Figure 3UV-visible spectra recorded in methanol of ferrozine, complexes (1) and (2) (a) and ferene, complexes (3) and (4) (b).
Elemental analysis data of complexes.
| Complex | Value | C (%) | H (%) | N (%) |
|---|---|---|---|---|
| ( | Calculated | 32.12 | 3.98 | 7.14 |
| Experimental | 31.68 | 3.80 | 7.42 | |
|
| ||||
| ( | Calculated | 39.66 | 3.25 | 9.03 |
| Experimental | 39.29 | 3.76 | 9.23 | |
|
| ||||
| ( | Calculated | 32.16 | 2.54 | 8.82 |
| Experimental | 32.12 | 2.76 | 9.29 | |
|
| ||||
| ( | Calculated | 33.78 | 1.89 | 9.55 |
| Experimental | 33.76 | 2.42 | 9.58 | |
Mean inhibition zone diameter at 1 mg/disc of complexes (1) and (2) and at 20 μg/disc of gentamicin.
| Mean inhibition zone diameter ± SEM (mm) | ||
|---|---|---|
|
|
| |
| Complex ( | 8.75 ± 0.75 | 7.50 ± 1.00 |
| Complex ( | 7.00 ± 0.00 | 7.75 ± 0.25 |
| Positive control (gentamicin) | 26.00 ± 1.50 | 30.75 ± 0.75 |
| Negative control | ND | ND |
ND, not detected.
Mean inhibition zone diameter for Candida albicans at 1 mg/disc of ferrozine and at 1 mg/disc of fluconazole.
| Mean inhibition zone diameter ± SEM (mm) | |
|---|---|
| Ferrozine | 13.00 ± 2.00 |
| Fluconazole | 29.75 ± 0.25 |